These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24363056)

  • 1. Design, synthesis and binding properties of a fluorescent α₉β₁/α₄β₁ integrin antagonist and its application as an in vivo probe for bone marrow haemopoietic stem cells.
    Cao B; Hutt OE; Zhang Z; Li S; Heazlewood SY; Williams B; Smith JA; Haylock DN; Savage GP; Nilsson SK
    Org Biomol Chem; 2014 Feb; 12(6):965-78. PubMed ID: 24363056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist.
    Cao B; Zhang Z; Grassinger J; Williams B; Heazlewood CK; Churches QI; James SA; Li S; Papayannopoulou T; Nilsson SK
    Nat Commun; 2016 Mar; 7():11007. PubMed ID: 26975966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1.
    Pepinsky RB; Mumford RA; Chen LL; Leone D; Amo SE; Riper GV; Whitty A; Dolinski B; Lobb RR; Dean DC; Chang LL; Raab CE; Si Q; Hagmann WK; Lingham RB
    Biochemistry; 2002 Jun; 41(22):7125-41. PubMed ID: 12033947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
    Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The integrin ligand SVEP1 regulates GPCR-mediated vasoconstriction via integrins α9β1 and α4β1.
    Morris GE; Denniff MJ; Karamanavi E; Andrews SA; Kostogrys RB; Bountziouka V; Ghaderi-Najafabadi M; Shamkhi N; McConnell G; Kaiser MA; Carleton L; Schofield C; Kessler T; Rainbow RD; Samani NJ; Webb TR
    Br J Pharmacol; 2022 Nov; 179(21):4958-4973. PubMed ID: 35802072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.
    Lin Kc; Ateeq HS; Hsiung SH; Chong LT; Zimmerman CN; Castro A; Lee WC; Hammond CE; Kalkunte S; Chen LL; Pepinsky RB; Leone DR; Sprague AG; Abraham WM; Gill A; Lobb RR; Adams SP
    J Med Chem; 1999 Mar; 42(5):920-34. PubMed ID: 10072689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAM12 and alpha9beta1 integrin are instrumental in human myogenic cell differentiation.
    Lafuste P; Sonnet C; Chazaud B; Dreyfus PA; Gherardi RK; Wewer UM; Authier FJ
    Mol Biol Cell; 2005 Feb; 16(2):861-70. PubMed ID: 15574885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
    Reger TS; Zunic J; Stock N; Wang B; Smith ND; Munoz B; Green MD; Gardner MF; James JP; Chen W; Alves K; Si Q; Treonze KM; Lingham RB; Mumford RA
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1173-6. PubMed ID: 20022493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural requirements of MLD-containing disintegrins for functional interaction with alpha 4 beta 1 and alpha 9 beta1 integrins.
    Bazan-Socha S; Kisiel DG; Young B; Theakston RD; Calvete JJ; Sheppard D; Marcinkiewicz C
    Biochemistry; 2004 Feb; 43(6):1639-47. PubMed ID: 14769041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM disintegrin-like domain recognition by the lymphocyte integrins alpha4beta1 and alpha4beta7.
    Bridges LC; Sheppard D; Bowditch RD
    Biochem J; 2005 Apr; 387(Pt 1):101-8. PubMed ID: 15504110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the molecular basis for α4β1 integrin antagonism.
    Hutt OE; Saubern S; Winkler DA
    Bioorg Med Chem; 2011 Oct; 19(19):5903-11. PubMed ID: 21889349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.
    Peng L; Liu R; Marik J; Wang X; Takada Y; Lam KS
    Nat Chem Biol; 2006 Jul; 2(7):381-9. PubMed ID: 16767086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
    Vanderslice P; Woodside DG; Caivano AR; Decker ER; Munsch CL; Sherwood SJ; Lejeune WS; Miyamoto YJ; McIntyre BW; Tilton RG; Dixon RA
    Biochem Biophys Res Commun; 2010 Oct; 400(4):619-24. PubMed ID: 20807504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
    Carstanjen D; Gross A; Kosova N; Fichtner I; Salama A
    Transfusion; 2005 Jul; 45(7):1192-200. PubMed ID: 15987366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engagement of integrin alpha4beta1 enhances thrombopoietin-induced megakaryopoiesis.
    Fox NE; Kaushansky K
    Exp Hematol; 2005 Jan; 33(1):94-9. PubMed ID: 15661402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha4beta1-integrin activation is necessary for high-efficiency T-cell subset interactions with VCAM-1 under flow.
    Lim YC; Wakelin MW; Henault L; Goetz DJ; Yednock T; Cabañas C; Sánchez-Madrid F; Lichtman AH; Luscinskas FW
    Microcirculation; 2000 Jun; 7(3):201-14. PubMed ID: 10901499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin alpha4beta1: VCAM-1, mucosal addressin cell adhesion molecule-1, and fibronectin induce distinct conformational changes.
    Newham P; Craig SE; Clark K; Mould AP; Humphries MJ
    J Immunol; 1998 May; 160(9):4508-17. PubMed ID: 9574557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.
    Dyatkin AB; Gong Y; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Hornby PJ; Diamond C; Kinney WA; Maryanoff BE; Damiano BP; He W
    Bioorg Med Chem; 2005 Dec; 13(24):6693-702. PubMed ID: 16112583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.
    Castanedo GM; Sailes FC; Dubree NJ; Nicholas JB; Caris L; Clark K; Keating SM; Beresini MH; Chiu H; Fong S; Marsters JC; Jackson DY; Sutherlin DP
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2913-7. PubMed ID: 12270174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of the integrin alpha9beta1 in bovine aortic valve interstitial cells.
    Wiester LM; Giachelli CM
    J Heart Valve Dis; 2003 Sep; 12(5):605-16. PubMed ID: 14565714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.